Cargill and Evolva have published their patent application relating to the production of sweeteners including Reb M through fermentation.

Related tags:
Stevia, Cargill, Evolva, Patent, Reb M, Sweeteners

A new patent application that covers the efficient and sustainable production of sweeteners including Rebaudioside M (Reb M) using fermentation technology has been published by Evolva and Cargill.

Cargill and Evolva Holding SA have been working on a joint development programme to develop and produce minor steviol glycosides - the compounds responsible for the sweet taste in the stevia leaf – via fermentation technologies since March last year
.

Since then the two firms have been working together to develop the new technology and set up a timetable for the scale-up and eventual production of steviol glycosides produced by fermentation. Indeed, the companies announced that their programme was moving into pilot-scale ahead of schedule
in late 2013, and news of further a further ‘technical milestone’
was released in early 2014.

Now Evolva and Cargill have set out their application for a patent on a process to ‘efficiently and sustainably produce next-generation sweeteners via fermentation’. The patent application (WO2014122227
) was originally filed in February 2013.

Fermentation process to improve flavour

The ability to produce a Reb M sweetener via fermentation opens up the potential to significantly improve the flavour profile of such zero-calorie sweeteners, especially at higher usage levels, said Evolva and Cargill in a press release.

The firms noted that the best tasting and sweetest parts of the stevia leaf - such as Reb M - make up less than 1% of the leaf. By producing Reb M using fermentation, the companies are able to produce the desired sweetness at a scale and cost that is not feasible through extraction of Reb M from the stevia leaf.

“This breakthrough will allow consumers all over the world to enjoy products using Reb M at a commercially viable price,” said Neil Goldsmith, CEO of Evolva. “This patent application forms part of our ever-expanding IP portfolio on steviol glycosides, which we are confident is the most extensive, and the most commercially significant in this space.”

This content is copyright protected

However, if you would like to share the information in this article, you may use the headline, summary and link below: